XilonixTM blocks the IL-1α produced by the body in response to tumor growth and it is being tested in an FDA fast tracked, pivotal phase 3 study for the treatment of metastatic colorectal cancer (NCT02138422, NCT01767857). Here, IL1A is linked to metastatic colorectal cancer.